Q3 2012 · —
Revenue$34.00K$34.00K no prior Q3 2011 on file−93.6% vs Q2 2012
Net income—
EPS Diluted-$1.97-$1.97 no prior Q3 2011 on fileN/M vs Q2 2012
Operating Income-$3,635,000—
Margins · derived
Operating margin-10691.2%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
no prior Q3 2011 on file
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Karyopharm Therapeutics Inc. · CIK 1503802 · Engraved from SEC EDGAR